By Robert Taylor Few opportunities exist to invest in and enhance benefit programs. The past decade has seen significant benefit cost inflation driven by drug costs and newer expensive drug therapies. Although the historical double digit health inflation trend appears to have slowed slightly in the past two years, there remains little appetite to [...]


Twitter
